Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Karyopharm Therapeutics Inc. - Common Stock (NQ:KPTI)

5.700 -0.370 (-6.10%)
Streaming Delayed Price Updated: 10:21 AM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karyopharm Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q3 2025 Revenue Beat and Earnings Miss
Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026. 
Via Chartmill
Topics Earnings
Earnings Scheduled For November 3, 2025
 
Via Benzinga
Karyopharm Therapeutics Earnings Preview
 
Via Benzinga
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial. 
Via Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Earnings Outlook For Karyopharm Therapeutics
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Earnings Scheduled For February 19, 2025
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-08-15: top gainers and losers in today's session.
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
 
Via Benzinga
Earnings Scheduled For August 11, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
What's going on in today's session
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript
KPTI earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
KPTI earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
KPTI earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.